Last updated: May 24, 2026
Lamotrigine’s supply chain splits into (1) API manufacturers and (2) finished-dose producers for US-labeled tablets and generics. In the US, supplier visibility is driven by FDA’s Orange Book (labeled products and holders) and drug master files (DMFs). Without specific product strength (IR vs XR), dosage form, market (US vs EU vs ROW), or a target brand/generic, the supplier universe cannot be stated completely or accurately.
Which companies supply lamotrigine API (active pharmaceutical ingredient)?
The lamotrigine API market is typically supplied by global fine-chemical manufacturers that file APIs through DMFs to support multiple generic applications. Finished-dose suppliers then buy API and formulate into immediate-release (IR) tablets or extended-release (XR) tablets, plus excipient systems and blending/granulation lines.
What API suppliers appear most often across generic lamotrigine products?
Lamotrigine generics are frequently sourced from established generic API ecosystems in India and China, with some European and US-linked producers supplying DMFs to multiple application holders. The most actionable approach is to map API DMFs and confirmed manufacturing sites to Orange Book application holders for the specific US strengths and dosage forms.
How do DMFs affect identifying lamotrigine suppliers?
DMFs tie an applicant to an API manufacturing site through references in Abbreviated New Drug Applications (ANDAs). Supplier lists differ by:
- Strength (25 mg, 50 mg, 100 mg, 150 mg, 200 mg)
- Dosage form (IR vs XR)
- Territory and labeling (US vs EU)
- Whether the applicant is also a branded-labeler or a repackager
What finished-dose manufacturers make lamotrigine tablets in the US?
Finished-dose manufacturers are listed implicitly through the Orange Book “Applicant/Holder” and explicitly in some cases through labeler and manufacturing site disclosures. Lamotrigine tablets are commonly produced by large generic manufacturers with multi-product solid oral plants.
Which dosage forms exist for lamotrigine that change supplier mapping?
Supplier mapping differs sharply between:
- Immediate-release lamotrigine tablets (most common)
- Extended-release lamotrigine (a narrower set of product introductions and manufacturing setups)
How many strengths change lamotrigine supplier coverage?
Each listed strength can have different ANDA holders, different manufacturing networks, and different formulation IP packages. Even when the same labeler is listed, the manufacturing site can vary by strength.
What does the Orange Book show for lamotrigine suppliers and product holders?
Orange Book entries identify:
- Drug substance name and strength
- Dosage form
- Applicant/Holder
- Patent and exclusivity status (which can indirectly affect which suppliers have long-running ANDA portfolios)
How to use Orange Book status to infer which suppliers are most active
Products with multiple listed strengths and long-standing ANDA approvals tend to have stable sourcing and repeat production runs. Products with fewer strengths often depend on fewer manufacturing sites.
How does regulatory pathway (ANDA vs 505(b)(2)) change supplier identification for lamotrigine?
Lamotrigine generics in the US are almost entirely ANDA-driven. Supplier visibility depends on:
- Whether an ANDA references a specific API DMF (more direct supplier mapping)
- Whether the applicant manufactures in-house or uses a contract manufacturer
- Whether the product is marketed under a labeler that is not the manufacturing site owner
Which contract manufacturing organizations (CMOs) support lamotrigine tablets?
Lamotrigine solid oral manufacturing requires:
- Tablet compression and coating capabilities
- Blend uniformity controls
- Strong QA systems for impurity profile control (lamotrigine is impurity-sensitive)
- Scale-up compatibility with generic dissolution targets
CMOs typically supply multiple generic oral brands and may produce for multiple ANDA holders, so the supplier name can appear only indirectly through manufacturing site listings or public inspections.
What manufacturing/IP barriers constrain new lamotrigine suppliers?
Key barriers include:
- Process validation and impurity control for lamotrigine API and finished tablets
- Regulatory history for specific plants (inspection outcomes affect approvals)
- Bioequivalence testing requirements for formulation changes or new strengths
- Submission history: suppliers often become “locked in” by DMF references and validated manufacturing processes
What is the supplier landscape for lamotrigine in Europe and other markets?
EU supply tends to distribute across:
- European generic manufacturers with locally compliant manufacturing
- Parallel imports affecting who is “visible” in-country
- Different regulatory data access, where DMF and manufacturer site visibility differs from the US
Key Takeaways
- Lamotrigine supply splits between API DMF-filed manufacturers and finished-dose tablet/XR manufacturers.
- The most accurate supplier list is product-specific (strength and IR vs XR) and territory-specific (US vs EU vs ROW).
- Orange Book and ANDA-driven DMF referencing are the mechanisms that connect label holders to actual manufacturing sites.
- Without a specified lamotrigine product (strength, IR/XR, and jurisdiction), a complete supplier roster cannot be stated accurately.
FAQs
- How can I identify lamotrigine API suppliers for a specific ANDA in the US?
- Do lamotrigine XR and IR tablets use the same manufacturing network?
- Which datasets best map lamotrigine tablet manufacturing sites to Orange Book holders?
- What impurity-control requirements most affect lamotrigine API and finished-dose approval?
- How do Paragraph IV filings typically change the sourcing and production readiness of lamotrigine suppliers?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (US FDA). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- FDA. Drugs@FDA (lamotrigine product and application records). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- FDA. Review and approval processes for ANDAs (overview). https://www.fda.gov/drugs/abbreviated-new-drug-application-anda
